Bank of America heads into the final days of July with the options alarm that defined last week quietly fading — and the Street still reluctant to get off the accelerator on price targets.
The most notable shift from the prior note is in options sentiment. Last week's report flagged a put/call ratio running more than two standard deviations above its 20-day mean, the most defensive reading since mid-June. That stress has unwound. The ratio has eased back to 1.11, barely a tenth of a standard deviation above its 20-day average of 1.11 — effectively neutral. The spike to 1.21 on July 24 now looks like post-earnings noise rather than a sustained hedging posture. Elsewhere in the borrow market, the story remains one of deep disinterest from the short side. Short interest nudged up 3% on the week to 1.26% of the free float, reversing a small piece of the month's 14% decline, but at 92 million shares it remains far below the 108 million recorded in late June. Cost to borrow more than halved over the week to 0.23% — barely worth noting in absolute terms. Availability is effectively unlimited, with over 2.4 billion shares available to lend. Nothing in the lending market suggests short sellers are building a fresh thesis.
The analyst community has spent the fortnight since the Q2 print ratcheting targets higher across the board. The overwhelming direction has been raises — Evercore, RBC, Truist, KBW, Barclays, Wells Fargo, and UBS all lifted targets in the days following the July 14 earnings beat, with Barclays carrying the highest on the Street at $72 and KBW close behind at $70. The consensus mean target now sits at $68.68, about 10% above the current $62.62 close. Bulls point to 7.2% revenue growth, a 9% rise in net interest income, and a 21% year-on-year jump in consumer banking net income. Bears focus on a CET1 ratio that slipped to 11.2% and an SLR down 20 basis points to 5.5%, raising questions about capital headroom at a time when the regulatory environment remains unsettled. Valuation has moved with the stock: the price-to-earnings multiple has expanded roughly 0.4x over the past month to 12.5x, and price-to-book has climbed to 1.49x from around 1.38x four weeks ago. Neither multiple looks stretched for a bank of this quality, but both are now closer to the top of the post-crisis range than the middle.
The ownership picture reinforces the sense that this is a widely-held, consensus-long name rather than a battleground stock. BlackRock added 4.75 million shares as of June 30, bringing its stake to 7.7% of the company. Capital Research added 8.5 million shares over the same period. Berkshire Hathaway — the second-largest holder at 7.3% — trimmed 3.7 million shares in the March quarter, a continuation of the gradual reduction that has been visible for several reporting periods. The insider picture is similarly clean: CEO Brian Moynihan's monthly award-and-sell program generated a $1.1 million disposal at $61.59 on July 15, consistent with the programmatic sales at $55.87 in June and $54.32 in April. These are mechanical, not discretionary.
The peer comparison adds a useful lens. JPMorgan gained 3.5% on the week, outperforming BAC's 2.3%, while Wells Fargo slipped 1% — suggesting some differentiation within the large-bank group, with BAC holding a middle position. Truist and Citizens both added around 1.3-2.6% on the day, reflecting a broadly constructive tone across the sector.
The next scheduled catalyst is Q3 earnings on October 14. Between now and then, the debate will centre on whether the NII momentum that drove the Q2 beat holds as the rate environment evolves — and whether the capital ratios can stabilise after the recent slip. Options traders are no longer hedging aggressively at this price; the question is whether that complacency is warranted or premature.
See the live data behind this article on ORTEX.
Open BAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
